Skip to content

Alkermes ALKS Interest coverage

Interest coverage at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-1.4×-3.2×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-19.2×-4.6×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
101×+77.4×
Arrowhead Research logo
Arrowhead ResearchARWR
-2.4×+0.9×
ALN
Alnylam PharmaceuticalsALNY
3.4×+2.9×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-7.1×-0.8×

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Calculated from Alkermes’s reported figures.

Based on trailing twelve months.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's interest coverage?
Alkermes (ALKS) reported interest coverage of 5.8× in Q1 2026.
How has Alkermes's interest coverage changed year-over-year?
Alkermes's interest coverage decreased by 75.4% year-over-year, from 23.6× to 5.8×.
What is the long-term trend for Alkermes's interest coverage?
Over 4 years (2020 to 2025), Alkermes's interest coverage has grown at a 12.3% compound annual growth rate (CAGR), from -13× to 20.7×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.